Today: 12 November 2025
Subscribe
Browse Category

NYSE:PFE News 4 November 2025 - 11 November 2025

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs (maximum $86.25 per share). The structure, which Metsera’s board deemed superior on value and certainty of closing, is expected to go to a shareholder vote on Nov. 13 before closing. Reuters+1 While Novo Nordisk pushed the bidding to similar headline value, meticulous antitrust calculus tipped the field. Reuters Breakingviews reports that FTC outreach helped steer Metsera toward Pfizer; coupled with
11 November 2025
 ·  ·  ·  ·  ·  ·  · 
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure. Key takeaways (Nov. 10) What changed today The revised terms, line by line (from today’s 8‑K) Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement: Why Novo bowed out — and the FTC’s
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
Nasdaq Rally Hits Speed Bump as Tech Stocks Wobble – Fed Warning and AI Jitters Shake Markets (Sept 24–25, 2025)

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Published: November 10, 2025 Key takeaways Market snapshot: AI leads early rebound U.S. index futures moved higher Monday as Senate action over the weekend boosted hopes for a stopgap funding bill to end the record federal shutdown. Nasdaq 100 futures led gains and AI bellwether Nvidia (NASDAQ: NVDA) traded about 3% higher premarket, pacing a broader chip bounce. Reuters Adding to the tone, Nvidia CEO Jensen Huang said over the weekend that demand for the company’s next‑gen Blackwell platform remains “very strong,” underscoring continued wafer needs from TSMC. The remarks come as investors look to AI hardware leaders to reassert
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Published: November 10, 2025 Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board intensified as Norway’s $1.5 trillion sovereign wealth fund said it would abstain from key votes this week. Separately, Novo struck a distribution pact in India to sell a new branded version of its semaglutide weight‑loss shot. Reuters+3Reuters+3Reuters+3 Key takeaways How NVO and PFE are trading today Pfizer seals Metsera deal: what’s in it and why it matters Pfizer’s agreement to
10 November 2025
 ·  ·  ·  ·  ·  · 
Tariff Shock and Fed Jitters: Asian Markets Stumble as Rally Meets Reality

What to Know Before the U.S. Stock Market Opens Today (Nov. 10, 2025): Futures Jump on Shutdown-Deal Hopes; Tyson, Occidental and AI Mega-Caps in Focus

TL;DR Futures and Global Backdrop U.S. equities are set to open higher Monday as traders react to signs of progress in Washington. Pre‑market, S&P 500 and Nasdaq‑100 futures rose while Dow futures edged up, tracking a global relief rally after the Senate took a procedural step toward ending the 40‑day federal shutdown. European and Asian bourses also advanced overnight. Reuters+1 The bid for risk assets follows a bruising week for U.S. tech where AI leaders led declines; today’s bounce centers on expectations that reopening the government would remove a growth headwind and reduce near‑term policy uncertainty. Washington: A Path to
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Key takeaways What happened today Pfizer’s final, sweetened bid prevailed after a week of public twists that included legal skirmishes and regulatory warnings. Metsera said the legal and regulatory risks tied to Novo’s proposal—flagged by the FTC—were “unacceptably high,” tipping the
8 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Last updated: Nov 7, 2025 (19:23 UTC) Pfizer (NYSE: PFE) shares were trading around $24.28, down roughly 2.3% intraday, as investors weighed new twists in the Metsera takeover fight and marked today’s dividend record date. As of the latest print, the stock’s day range was $24.12–$24.61 on heavy volume. Key takeaways Pfizer stock price today (intraday) What changed today — Nov 7, 2025 1) Metsera bidding war heats up Why it matters: The Metsera outcome could reshape Pfizer’s cardiometabolic/obesity ambitions after earlier setbacks, and investors are repricing PFE daily on any signal of who ultimately wins—and at what cost. Financial
7 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Key takeaways What happened today (Nov. 6) 1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1 2) Pfizer signals a sweeter counter—because the clock is tight.Reporting overnight indicates Pfizer plans to sweeten
6 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine (Comirnaty) and antiviral pill (Paxlovid). However, with the pandemic’s tide receding, Pfizer’s stock (PFE) has faced significant challenges in 2023–2025. Shares that once traded above $50 during the vaccine rollout now hover in the mid-$20s reuters.com. At around $24–$25 per share, Pfizer’s market cap is about $138 billion stockanalysis.com – substantially smaller than several years ago
5 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone reuters.com reuters.com. The share price is now hovering in the low $70s reuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emerged prnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4 reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Detailed Analysis and Outlook Stock Price Trends and Technical Analysis Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week range ($20.92 – $28.00) marketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s (a ~10% jump) following its government pricing deal announcement marketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However,
4 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share reuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performance reuters.com reuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal” reuters.com. This was weeks
4 November 2025
 ·  ·  ·  ·  ·  · 
1 2 3
Go toTop